NEW YORK, April 21 (UPI) — U.S. cancer researchers say an experimental drug is providing effective targeted therapy in treating an aggressive form of advanced prostate cancer.
Memorial Sloan-Kettering Cancer Center scientists said a new multicenter study suggests the drug — MDV3100 — is safe and effective for patients with castration-resistant prostate cancer. Such cancers are known for their poor prognosis and limited treatment options.
The scientists said the combined Phase 1 and 2 study found MDV3100 not only shrank patients’ tumors, but also reduced serum levels of the tumor marker prostate-specific antigen, stabilized disease that had spread to soft tissues and the bone, and reduced the number of circulating tumor cells in the blood.
“We were encouraged to see anti-tumor activity in men whose disease had spread to other parts of the body after either becoming resistant to previous hormone treatments or progressing following chemotherapy,” said Dr. Howard Scher, chief of the Sloan-Kettering’s Genitourinary Oncology Service and the study’s lead author. “These findings strengthen the drug’s potential to change the outlook for a group of patients who currently have limited effective treatment options from which to choose.”
The study appears online, ahead of print, in The Lancet.
Copyright 2010 United Press International, Inc. (UPI). Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI’s prior written consent.